Cheteh, Emarndeena H
Augsten, Martin
Rundqvist, Helene
Bianchi, Julie
Sarne, Victoria
Egevad, Lars
Bykov, Vladimir JN
Östman, Arne
Wiman, Klas G
Article History
Received: 7 December 2016
Revised: 30 March 2017
Accepted: 20 April 2017
First Online: 1 June 2017
Competing interests
: KGW and VJNB are co-founders and shareholders of Aprea Therapeutics AB, a company that develops novel p53-based cancer therapy. KGW is a member of its Clinical Advisory Board. The remaining authors declare no conflict of interest.